IDEXX LABORATORIES INC /DE
10-Q, EX-27, 2000-11-13
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: IDEXX LABORATORIES INC /DE, 10-Q, 2000-11-13
Next: IDEXX LABORATORIES INC /DE, 10-Q, EX-10.1, 2000-11-13



<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE IDEXX
LABORATORIES, INC. CONSOLIDATED FINANCIAL STATEMENTS AS OF AND FOR THE NINE
MONTHS ENDED SEPTEMBER 30, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>
<CIK> 0000874716
<NAME> IDEXX LABORATORIES, INC.
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<EXCHANGE-RATE>                                      1
<CASH>                                          38,726
<SECURITIES>                                    47,278
<RECEIVABLES>                                   67,152
<ALLOWANCES>                                     4,791
<INVENTORY>                                     62,870
<CURRENT-ASSETS>                               234,167
<PP&E>                                          97,491
<DEPRECIATION>                                  55,738
<TOTAL-ASSETS>                                 354,360
<CURRENT-LIABILITIES>                           87,956
<BONDS>                                              0
                                0
                                          0
<COMMON>                                         4,016
<OTHER-SE>                                     262,388
<TOTAL-LIABILITY-AND-EQUITY>                   354,360
<SALES>                                        208,341
<TOTAL-REVENUES>                               274,813
<CGS>                                           86,641
<TOTAL-COSTS>                                  140,557
<OTHER-EXPENSES>                                94,711
<LOSS-PROVISION>                                   644
<INTEREST-EXPENSE>                                 167
<INCOME-PRETAX>                                 42,812
<INCOME-TAX>                                    15,981
<INCOME-CONTINUING>                             26,831
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    26,831
<EPS-BASIC>                                        .77
<EPS-DILUTED>                                      .73


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission